What's Going On With Aralez Pharmaceuticals?

Shares of Aralez Pharmaceuticals Inc ARLZ, a specialty pharmaceutical company, fell nearly 11 percent on Wednesday ahead of an expected U.S. Food and Drug Administration ruling for its Yosparala therapy.

Aralez's therapy helps prevent cardiovascular disease in patients at-risk for aspirin induced ulcers. Some experts suggested it's "highly likely" Yosprala will be approved by the FDA by the September 14 PDUFA date, which would pave a path towards a commercial launch in the fourth quarter of 2016.

Shares of Aralez were trading lower by more than 12 percent in Thursday's pre-market trading session as no update was provided by the company. However, the stock was halted around 7:10 a.m. ET for pending news.

As of 8:00AM ET there has been no official announcement. Twitter users were mixed on the lack of data as some investors are bracing for potential bad news while others are optimistic.

$ARLZ really? halted an hour now with no PR

— Shane Blackmon (@shaneblackmon) September 15, 2016

$arlz seeks to have longest halt in market history.. halt until next Monday, while speculators are in IC unit unable to deal with wait

— stephen (@Phoenix3million) September 15, 2016

@getbillasap no news good news, until no news is bad news, which is usually good news, but sometimes not $ARLZ

— Steve Feffer (@sfef84) September 15, 2016

come on. Good or bad, just release the news already! $ARLZ

— BioResearch (@BioResearchFund) September 15, 2016